Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 6, November-December, p. 1099–1104

doi: 10.17219/acem/27093

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The Dry Form of Age-Related Macular Degeneration (AMD): The Current Concepts of Pathogenesis and Prospects for Treatment

Hanna M. Zając-Pytrus1,A,B,C,D, Agnieszka Pilecka2,A,B,C, Anna Turno-Kręcicka1,E, Joanna Adamiec-Mroczek1,E, Marta Misiuk-Hojło1,F

1 Department of Ophthalmology, Wroclaw Medical University, Poland

2 The Higher School of Humanities, Leszno, Poland

Abstract

Age-related macular degeneration (AMD) is a disease that causes varying degrees of blindness, which afflicts millions of adults in their later years. Preliminary changes occur during normal aging, but in some individuals the pathology leads to the development of AMD. The pathology seems to be a mixture of biochemical, cellular, and molecular events. Lipofuscinogenesis and early drusen genesis are in the early stages of AMD and their inhibition or reversal would dramatically increase the quality of vision in elderly people. The disease is characterized by abnormal extracellular deposits, known as drusen, which accumulate along the basal surface of the retinal pigmented epithelium RPE. Widespread drusen deposition is associated with retinal pigmented epithelial cell dysfunction and degeneration of the photoreceptors. Recent studies have shown that drusen contain a variety of immunomodulatory molecules, suggesting that the process of drusen formation involves local inflammatory events, including activation of the complement cascade. Molecular pathways involved in the etiology of this disease and the potential prospects of its treatment will be presented on the basis of the results of the current studies.

Key words

dry AMD pathogenesis, dry AMD treatment, dry AMD prophylaxis

References (33)

  1. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP: Smoking and age-related macular degeneration: a review of association. Eye 2005, 19, 935–944.
  2. DeBlack SS: Cigarette smoking as a risk factor for cataract and age related macular degeneration: a review of the literature. Optometry 2003, 74, 99–110.
  3. HagemanGS, Luthert PJ, Chong NHV, Johnson LV, Anderson DH, Mullins RF: An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch’s Membrane Interface in Aging and Age-Related Macular Degeneration. Prog Retin Eye Res 2001, 20, 705–732.
  4. Bergmann M, Schutt F, Holz FG, Kopitz J: Inhibition of the ATP-driven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2-E may contribute to the pathogenesis of age-related macular degeneration. FASEB J 2004, 18, 562–564.
  5. Finnemann SC, Leung LW, Rodriguez-Boulan E: The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium. Proc Natl Acad Sci USA 2002, 99, 3842–3847.
  6. Weismann D, Hartvigsen K, Lauer N: Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011, 478, 76–81.
  7. Eskelinen EL: New insights into the mechanisms of macroautophagy in mammalian cells. Int Rev Cell Mol Biol 2008, 266, 207–247.
  8. Wang AL, Lukas TJ, Yuan M, Du N, Tso MO, Neufeld AH: Autophagy, exosomes and drusen formation in agerelated macular degeneration. Autophagy 2009, 5, 563–564.
  9. Wang AL, Lukas TJ, Yuan M, Du N, Tso MO, Neufeld AH: Autophagy and exosomes in the aged retinal pigment epithelium: possible relevance to drusen formation and age-related macular degeneration. PLoS One 2009, 4, 4160.
  10. Deangelis MM, Silveira AC, Carr EA, Kim IK: Genetics of age-related macular degeneration: current concepts, future directions. Semin Ophthalmol 2011, 26, 77–93.
  11. Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss AREDS report no. 8. Arch Ophthalmol 2001, 119, 1417–1436.
  12. Merle B, Delyfer MN, Korobelnik JF: Dietary omega-3 FA and the risk for ARM: the ALIENOR Study. IOVS 2011, 52, 6004–6011.
  13. Merle B, Delyfer MN, Korobelnik JF: Plasma omega 3-fatty acids and the risk for age-relatedmacular degeneration: the ALIENOR Study ARVO 2012:370; Program number 3813-A427.
  14. Delyfer MN, Buaud B, Korobelnik JF: Association of macular pigment density with plasma omega-3 fatty acids: the PIMAVOSA study. Invest Ophthalmol Vis Sci 2012, 53, 1204–1210.
  15. Stahl A, Krrhone TU, Sapieha P: Lipid metabolites in the pathogenesis and treatment of neovascular eye disease. Br J Ophthalmol 2011, 95, 1496–1501.
  16. Shalev V, Sror M, Goldstein I: Statin use and the risk of age-related macular degeneration in a large health organization in Israel. Opthalmic Epidemiol 2011, 18, 83–90.
  17. Seddon JM, Ajani UA, Sperduto RD: Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994, 272, 1413–1420.
  18. Moeller SM, Parekh N, Tinker L: Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women’s Health Initiative. Arch Ophthalmol 2006, 124, 1151–1162.
  19. Tan JS, Wang JJ, Flood V, Rochtchina E, Smith W, Mitchell P: Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2008, 115, 334–341.
  20. Parekh N, ChappellRJ, Millen AE: Association between vitamin D and age-related macular degeneration in the national health and nutrition examination survey. Arch Ophthalmol 2007, 125, 661–669.
  21. Millen AE, Voland E, Sondel SA: Vitamn D status and early age-related macular degeneration in postmenopausal women. Arch Ophthalmol 2011, 129, 481–493.
  22. Morrison MA, Silveira AC, Huynh N: Systems biology-based analysis implicates a novel role for vitamin D metabolism in the pathogenesis of AMD. Hum Genomics 2011, 5, 538–568.
  23. Lee V, Hoh Kam JH, Jeffery G: Vitamin D rejuvenates aging eyes by reducing inflammation, clearing amyloid beta and improving visual function. Neurobiol Aging 2012, PMID 22217419.
  24. Curcio CA, Johnson M, Rudolf M, Huang JD: The oil spill in ageing Bruch membrane. Br J Ophthalmol 2011, 95, 1638–1645.
  25. Curcio CA: Pathophysiology of Non-Neovascular Age-Related Macular Degeneration: The Oil Spill in Bruch’s Membrane and beyond. Ophthalmologica 2012, 228, Suppl 1, 23–25.
  26. Kang MY, Sim CM, Seok JH: Albumin diffusion across human Bruch’s membrane: modulation by ginseng compounds. ARVO 2012, 215: Program number 1595-A548.
  27. Ohno-Matsui K: Parallel findings in age-related macular degeneration and Alzheimer’s disease. Prog Retin Eye Res 2011, 30, 217–238.
  28. Armstrong RA: The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathol 2009, 47, 289–299.
  29. Isas JM, Luibl V, Johnson LV: Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci 2010, 51, 1304–1310.
  30. Curcio CA, Johnson M, Huang JD, Rudolfd M: Aging, age-related macular degeneration, and the response-toretention of apolipoprotein B-containing lipoproteins. Prog Retin Eye Res 2009, 28, 393–422.
  31. Tuo J, Smith BC, Bojanowski CM: The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. Faseb J 2004, 18, 1297–1299.
  32. Combadiere C, Feumi C, Raoul W: CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest 2007, 117, 2920–2928.
  33. Rickman B, Farsiu C, Toth C, Cynthia A: Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging. IOVS 2013, 54, 14, 68–80.
© Wroclaw Medical University